NO333599B1 - Anvendelse av distrontiumsalter av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre for fremstillingen av medikamenter for behandlingen av gastro-duodenal smerte - Google Patents
Anvendelse av distrontiumsalter av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre for fremstillingen av medikamenter for behandlingen av gastro-duodenal smerte Download PDFInfo
- Publication number
- NO333599B1 NO333599B1 NO20052562A NO20052562A NO333599B1 NO 333599 B1 NO333599 B1 NO 333599B1 NO 20052562 A NO20052562 A NO 20052562A NO 20052562 A NO20052562 A NO 20052562A NO 333599 B1 NO333599 B1 NO 333599B1
- Authority
- NO
- Norway
- Prior art keywords
- carboxymethyl
- treatment
- cyano
- amino
- carboxylic acid
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 150000003839 salts Chemical class 0.000 title claims abstract description 7
- 208000002193 Pain Diseases 0.000 title claims abstract description 6
- DJSXNILVACEBLP-UHFFFAOYSA-N ranelic acid Chemical class OC(=O)CN(CC(O)=O)C=1SC(C(O)=O)=C(CC(O)=O)C=1C#N DJSXNILVACEBLP-UHFFFAOYSA-N 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 2
- 229940079593 drug Drugs 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 206010013864 duodenitis Diseases 0.000 claims 1
- MWRNYSWUCMYRQX-UHFFFAOYSA-N C(=O)(O)CC(C=1C(=C(SC1C(=O)O)N)C#N)C(=O)O Chemical compound C(=O)(O)CC(C=1C(=C(SC1C(=O)O)N)C#N)C(=O)O MWRNYSWUCMYRQX-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- ZHEZAQJNZMLYBA-UHFFFAOYSA-J distrontium;5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate;octahydrate Chemical compound O.O.O.O.O.O.O.O.[Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N ZHEZAQJNZMLYBA-UHFFFAOYSA-J 0.000 description 9
- 229940079488 strontium ranelate Drugs 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229910001631 strontium chloride Inorganic materials 0.000 description 2
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 2
- 159000000008 strontium salts Chemical class 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- -1 glosses Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Den foreliggende oppfinnelse vedrører anvendelsen av distiontiumsaltet av 2-psr,N- di(karboksymetyl)aminol-3-cyano-4-karboksymetyltiofen-5-karboksylsyre for å fremstille medikamenter tiltenkt for behandlingen av gastio-duodenal smerte.
Description
Foreliggende oppfinnelse vedrører anvendelse av distrontiumsaltet av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre for å fremstille medikamenter tiltenkt behandlingen av gastro-duodenal smerte.
Distrontiumsaltet av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre har blitt beskrevet i patentbeskrivelse EP 0 415 850. Dets anti-osteoporotiske egenskaper tillater det å bli anvendt i bensykdommer slik som osteoporose. Det kan også anvendes i behandlingen av kutan og vaskulær aldring, leverforstyrrelser og dentaIforstyrrelser.
Distrontiumsaltet av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre har dessuten anti-artrosiske egenskaper som gjør det nyttig i behandlingen av artrose som beskrevet i patentbeskrivelse EP 0 813 869.
Søkeren har nå oppdaget at distrontiumsaltet av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre med formel (I) og hydrater derav har gastrobeskyttende egenskaper som tillater deres anvendelse for å fremstille medikamenter tiltenkt for behandlingen av gastro-duodenal smerte:
Faktisk har det blitt vist i en klinisk studie at forbindelsen med formel (I), som også refereres til som strontiumranelat, var i stand til å bevirke en signifikant forbedring i magesmerte.
Dette resultat er desto mer overraskende ved at, under en in wVo-studie utført med et annet strontiumsalt (strontiumklorid), ble det observert at strontiumklorid svært raskt forårsaket overfladiske hemoragiske lesjoner i de behandlede dyr.
Fagmannen ville utvilsomt ikke ha forestilt seg at et annerledes strontiumsalt, i dette tilfelle strontiumranelat, ville tillate at den omvendte effekt oppnås.
Disse fullstendig overraskende resultater gjør det følgelig mulig å overveie anvendelse av strontiumranelat og hydrater derav for å oppnå farmasøytiske sammen setninger for anvendelse i behandlingen av gastro-duodenal smerte og spesielt gastritt og duodenitt og enhver inflammasjon av slimhinnen i magen enten akutt eller kronisk.
Gastritt og duodenitt tilsvarer irriterende tilstander i den digestive slimhinne som ledsages av daglig abdominal smerte i takt med måltider. De forverres av forskjellige typer mat eller alkoholholdige drikker. De kan gå forut for begynnelsen på ulcu-ser. De rettferdiggjør administrasjonen av forskjellige behandlinger for å beskytte slimhinnen eller for å redusere syresekresjon.
De farmasøytiske sammensetninger vil fremstilles i former egnet for administrasjon ved den orale, parenterale, transkutane, nasale, rektale eller perlingvale rute, spesielt i form av injiserbare preparater, tabletter, sublingvale tabletter, glossetter, gelatinkapsler, kapsler, lozengere, suppositorier, kremer, salver, dermale geler, etc.
I tillegg til strontiumranelat eller, hvor passende, hydrater derav, omfatter de far-masøytiske sammensetninger ifølge oppfinnelsen én eller flere eksipienser eller ve-hikler valgt fra fortynningsmidler, smøremidler, bindemidler, desintegrerende midler, absorbenter, fargestoffer, søtemidler, etc.
Med ikke-begrensende eksempel, kan det nevnes:
som fortynningsmidler: laktose, dekstrose, sukrose, mannitol, sorbitol, cellu-lose, glyserol,
som smøremidler: silika, talk, stearinsyre og dens magnesium- og kalsiums-alter, polyetylenglykol,
som bindemidler: aluminiumsilikat, magnesiumsilikat, stivelse, gelatin, tra-gant, metylcellulose, natriumkarboksymetylcellulose og polyvinylpyrrolidon,
som desintegrerende midler: agar, alginsyre og dens natriumsalt, brusende blandinger.
Den nyttige dosering varierer i henhold til pasientens kjønn, alder og vekt, admi-nistrasjonsruten, lidelsens natur og alle assosierte behandlinger, og strekker seg fra 25 mg til 6 g strontiumranelat per 24 timer, for eksempel fra 100 mg til 4 g forbin-delse per 24 timer.
Den daglige dose av strontiumranelat vil fortrinnsvis være 2 g per dag.
Klinisk studie:
Denne studie ble utført i 1649 pasienter. 719 ble behandlet med strontiumranelat, 723 ble behandlet med en placebo. Behandlingens varighet var 1101 ± 321 dager. Dosen av strontiumranelat administrert var 2 g/dag.
Etter behandling ble det observert at magesmerte ble signifikant redusert i gruppen av pasienter behandlet med strontiumranelat (minst 30 %) sammenlignet med gruppen av pasienter behandlet med placebo.
Claims (3)
1. Anvendelse av distrontiumsaltet av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre eller hydrater derav for å fremstille et medikament tiltenkt for behandlingen av gastro-duodenal smerte.
2. Anvendelse ifølge krav 1, hvori medikamentet er tiltenkt for behandlingen av gastritt.
3. Anvendelse ifølge krav 1, hvori medikamentet er tiltenkt for behandlingen av duodenitt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0213805A FR2846558B1 (fr) | 2002-11-05 | 2002-11-05 | Utilisation du sel distrontique de l'acide 2-n,n-di(carboxymethyl)amino-3-cyano-4-carboxymethyl- thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales |
| PCT/FR2003/003279 WO2004043455A1 (fr) | 2002-11-05 | 2003-11-04 | Utilisation du sel distrontique de l'acide 2-[n,n-di(carboxymethyl)amino]-3-cyano-4-carboxymethyl-thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052562L NO20052562L (no) | 2005-05-26 |
| NO333599B1 true NO333599B1 (no) | 2013-07-22 |
Family
ID=32104443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052562A NO333599B1 (no) | 2002-11-05 | 2005-05-26 | Anvendelse av distrontiumsalter av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre for fremstillingen av medikamenter for behandlingen av gastro-duodenal smerte |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7544710B2 (no) |
| EP (1) | EP1560578B1 (no) |
| JP (1) | JP4335146B2 (no) |
| KR (1) | KR100735348B1 (no) |
| CN (1) | CN1705479B (no) |
| AT (1) | ATE328591T1 (no) |
| AU (1) | AU2003292325B2 (no) |
| BR (1) | BR0315917A (no) |
| CA (1) | CA2503975C (no) |
| CY (1) | CY1105105T1 (no) |
| DE (1) | DE60305962T2 (no) |
| DK (1) | DK1560578T3 (no) |
| EA (1) | EA007863B1 (no) |
| ES (1) | ES2264010T3 (no) |
| FR (1) | FR2846558B1 (no) |
| GE (1) | GEP20084463B (no) |
| HK (1) | HK1084029A1 (no) |
| MA (1) | MA27406A1 (no) |
| MX (1) | MXPA05004792A (no) |
| NO (1) | NO333599B1 (no) |
| NZ (1) | NZ539516A (no) |
| PL (1) | PL214704B1 (no) |
| PT (1) | PT1560578E (no) |
| UA (1) | UA78618C2 (no) |
| WO (1) | WO2004043455A1 (no) |
| ZA (1) | ZA200503082B (no) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1534305E (pt) | 2003-05-07 | 2007-02-28 | Osteologix As | Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis |
| WO2005123098A2 (en) * | 2004-06-17 | 2005-12-29 | Osteologix A/S | Preventing gastrointestinal side-effects with strontium salts |
| US20070292535A1 (en) * | 2006-06-19 | 2007-12-20 | Tabbiner Philip S | Strontium compositions and methods of treating arthritic and or osteoporitic conditions |
| US20070292529A1 (en) * | 2006-06-19 | 2007-12-20 | Tabbiner Philip S | Strontium compositions and methods of treating osteoporotic conditions |
| EP2530068A1 (en) | 2011-05-31 | 2012-12-05 | Lacer, S.A. | New strontium salts, synthesis and use thereof in the treatment of osteoporosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2651497B1 (fr) * | 1989-09-01 | 1991-10-25 | Adir | Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| FR2740341B1 (fr) * | 1995-10-26 | 1997-12-19 | Oreal | Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau |
| FR2749759B1 (fr) | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
| FR2768621B1 (fr) * | 1997-09-22 | 2000-04-07 | Oreal | Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees |
| US6489356B2 (en) * | 2000-09-05 | 2002-12-03 | Edward Leung | Method for treating pain in humans |
-
2002
- 2002-11-05 FR FR0213805A patent/FR2846558B1/fr not_active Expired - Fee Related
-
2003
- 2003-04-11 UA UAA200505314A patent/UA78618C2/uk unknown
- 2003-11-04 AU AU2003292325A patent/AU2003292325B2/en not_active Ceased
- 2003-11-04 EP EP03767891A patent/EP1560578B1/fr not_active Expired - Lifetime
- 2003-11-04 DK DK03767891T patent/DK1560578T3/da active
- 2003-11-04 WO PCT/FR2003/003279 patent/WO2004043455A1/fr active IP Right Grant
- 2003-11-04 PT PT03767891T patent/PT1560578E/pt unknown
- 2003-11-04 AT AT03767891T patent/ATE328591T1/de active
- 2003-11-04 JP JP2004550731A patent/JP4335146B2/ja not_active Expired - Fee Related
- 2003-11-04 KR KR1020057007989A patent/KR100735348B1/ko not_active IP Right Cessation
- 2003-11-04 PL PL375960A patent/PL214704B1/pl unknown
- 2003-11-04 ES ES03767891T patent/ES2264010T3/es not_active Expired - Lifetime
- 2003-11-04 EA EA200500687A patent/EA007863B1/ru not_active IP Right Cessation
- 2003-11-04 BR BR0315917-5A patent/BR0315917A/pt not_active IP Right Cessation
- 2003-11-04 MX MXPA05004792A patent/MXPA05004792A/es active IP Right Grant
- 2003-11-04 NZ NZ539516A patent/NZ539516A/en not_active IP Right Cessation
- 2003-11-04 CN CN2003801018229A patent/CN1705479B/zh not_active Expired - Fee Related
- 2003-11-04 US US10/533,787 patent/US7544710B2/en not_active Expired - Fee Related
- 2003-11-04 DE DE60305962T patent/DE60305962T2/de not_active Expired - Lifetime
- 2003-11-04 CA CA2503975A patent/CA2503975C/fr not_active Expired - Fee Related
- 2003-11-04 GE GEAP20038823A patent/GEP20084463B/en unknown
-
2005
- 2005-04-14 MA MA28220A patent/MA27406A1/fr unknown
- 2005-04-15 ZA ZA200503082A patent/ZA200503082B/en unknown
- 2005-05-26 NO NO20052562A patent/NO333599B1/no not_active IP Right Cessation
-
2006
- 2006-04-11 HK HK06104385.9A patent/HK1084029A1/xx not_active IP Right Cessation
- 2006-07-24 CY CY20061101026T patent/CY1105105T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2600773C (en) | Benzamidine derivatives for treatment and prevention of cancer therapy induced mucositis | |
| NO333599B1 (no) | Anvendelse av distrontiumsalter av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre for fremstillingen av medikamenter for behandlingen av gastro-duodenal smerte | |
| DE69927497D1 (de) | Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklylamidverbindungen | |
| TWI721697B (zh) | 用於治療骨關節炎的化合物 | |
| WO2011008052A2 (ko) | 콜포신 다로페이트를 포함하는 골 질환의 예방 또는 치료용 조성물 | |
| RU2701720C1 (ru) | Комбинации пальмитоилэтаноламида для лечения хронической боли | |
| US20170079953A1 (en) | Melatonin and its use in preventing postoperative complications | |
| JPWO2002060457A1 (ja) | 抗ストレス剤 | |
| Qi et al. | Cyclic adenosine phosphate improves functional recovery after spinal cord injury via activating unfolded protein response | |
| JP2002265354A (ja) | 抗ピロリ菌剤組成物 | |
| AU614541B2 (en) | Choline diethyldithiocarbamate, a process for its preparation and therapeutic composition containing it | |
| ES2787223T3 (es) | Sales y composiciones útiles para tratar enfermedades | |
| CN112358477A (zh) | 一种用于治疗胆囊炎的药物及其制备方法 | |
| EA015503B1 (ru) | Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения черепно-мозговых травм | |
| JP2000016949A (ja) | 口内炎、消化管粘膜障害又は皮膚潰瘍の治療又は予防剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |